Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

The risk for graft loss 5 years after kidney transplantation is increased if cold ischaemia time exceeds 14 hours.

Hansson J, Mjörnstedt L, Lindnér P.

Clin Transplant. 2018 Aug 10:e13377. doi: 10.1111/ctr.13377. [Epub ahead of print]

PMID:
30098052
2.

Enhancing policy implementation to improve healthcare practices: The role and strategies of hybrid national-local support structures.

Granström E, Hansson J, Sparring V, Brommels M, Nyström ME.

Int J Health Plann Manage. 2018 Aug 9. doi: 10.1002/hpm.2617. [Epub ahead of print]

PMID:
30091487
3.

Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients.

Ahlén Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M, Lundgren C, Holmström B, Palmqvist K, Hansson J, Alamdari F, Huge Y, Aljabery F, Riklund K, Winerdal ME, Krantz D, Zirakzadeh AA, Marits P, Sjöholm LK, Sherif A, Winqvist O.

Clin Epigenetics. 2018 Aug 3;10(1):102. doi: 10.1186/s13148-018-0536-6.

4.

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9.

PMID:
30069041
5.

Leading top-down implementation processes: a qualitative study on the role of managers.

Uvhagen H, Hasson H, Hansson J, von Knorring M.

BMC Health Serv Res. 2018 Jul 18;18(1):562. doi: 10.1186/s12913-018-3360-y.

6.

Understanding the dynamics of sustainable change: A 20-year case study of integrated health and social care.

Klinga C, Hasson H, Andreen Sachs M, Hansson J.

BMC Health Serv Res. 2018 Jun 4;18(1):400. doi: 10.1186/s12913-018-3061-6.

7.

Exploring the potential of a multi-level approach to improve capability for continuous organizational improvement and learning in a Swedish healthcare region.

Nyström ME, Höög E, Garvare R, Andersson Bäck M, Terris DD, Hansson J.

BMC Health Serv Res. 2018 May 24;18(1):376. doi: 10.1186/s12913-018-3129-3.

8.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.

Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

9.

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.

Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R, Garcia-Ruiz C, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J, Hagström-Andersson AK.

Nat Commun. 2018 May 2;9(1):1770. doi: 10.1038/s41467-018-04180-1.

10.

Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells.

Guzzi N, Cieśla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, Pimková K, Sommarin MNE, Munita R, Lubas M, Lim Y, Okuyama K, Soneji S, Karlsson G, Hansson J, Jönsson G, Lund AH, Sigvardsson M, Hellström-Lindberg E, Hsieh AC, Bellodi C.

Cell. 2018 May 17;173(5):1204-1216.e26. doi: 10.1016/j.cell.2018.03.008. Epub 2018 Apr 5.

PMID:
29628141
11.

Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.

Winerdal ME, Krantz D, Hartana CA, Zirakzadeh AA, Linton L, Bergman EA, Rosenblatt R, Vasko J, Alamdari F, Hansson J, Holmström B, Johansson M, Winerdal M, Marits P, Sherif A, Winqvist O.

Cancer Immunol Res. 2018 May;6(5):528-538. doi: 10.1158/2326-6066.CIR-17-0466. Epub 2018 Mar 27.

PMID:
29588320
12.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.

Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.

13.

Factors influencing early stage healthcare-academia partnerships.

Uvhagen H, von Knorring M, Hasson H, Øvretveit J, Hansson J.

Int J Health Care Qual Assur. 2018 Feb 12;31(1):28-40. doi: 10.1108/IJHCQA-11-2016-0178.

PMID:
29504843
14.

Comprehensive Proteomic Characterization of Ontogenic Changes in Hematopoietic Stem and Progenitor Cells.

Jassinskaja M, Johansson E, Kristiansen TA, Åkerstrand H, Sjöholm K, Hauri S, Malmström J, Yuan J, Hansson J.

Cell Rep. 2017 Dec 12;21(11):3285-3297. doi: 10.1016/j.celrep.2017.11.070.

15.

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C.

Eur J Cancer. 2018 Mar;91:168-170. doi: 10.1016/j.ejca.2017.11.023. Epub 2017 Dec 7. No abstract available.

PMID:
29224903
16.

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. Erratum in: Nature. 2018 Aug 1;:.

PMID:
29144447
17.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J.

Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.

18.

Injury induced expression of caveolar proteins in human kidney tubules - role of megakaryoblastic leukemia 1.

Krawczyk KM, Hansson J, Nilsson H, Krawczyk KK, Swärd K, Johansson ME.

BMC Nephrol. 2017 Oct 24;18(1):320. doi: 10.1186/s12882-017-0738-8.

19.

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.

Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406.

20.

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Falkenius J, Johansson H, Tuominen R, Frostvik Stolt M, Hansson J, Egyhazi Brage S.

BMC Cancer. 2017 Aug 29;17(1):584. doi: 10.1186/s12885-017-3577-x.

21.

Fear or food - abundance of red fox in relation to occurrence of lynx and wolf.

Wikenros C, Aronsson M, Liberg O, Jarnemo A, Hansson J, Wallgren M, Sand H, Bergström R.

Sci Rep. 2017 Aug 22;7(1):9059. doi: 10.1038/s41598-017-08927-6.

22.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group.

J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.

PMID:
28830827
23.

Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.

Helgadottir H, Tuominen R, Olsson H, Hansson J, Höiom V.

J Am Acad Dermatol. 2017 Nov;77(5):893-901. doi: 10.1016/j.jaad.2017.05.050. Epub 2017 Aug 14.

PMID:
28818438
24.

Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes.

Lindgren D, Eriksson P, Krawczyk K, Nilsson H, Hansson J, Veerla S, Sjölund J, Höglund M, Johansson ME, Axelson H.

Cell Rep. 2017 Aug 8;20(6):1476-1489. doi: 10.1016/j.celrep.2017.07.043.

25.

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.

Sakil HAM, Stantic M, Wolfsberger J, Brage SE, Hansson J, Wilhelm MT.

Cell Oncol (Dordr). 2017 Dec;40(6):631-638. doi: 10.1007/s13402-017-0340-x. Epub 2017 Jul 4.

26.

Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.

Gordon D, Hansson J, Eloranta S, Gordon M, Gillgren P, Smedby KE.

Int J Cancer. 2017 Oct 1;141(7):1345-1354. doi: 10.1002/ijc.30843. Epub 2017 Jul 12.

PMID:
28635084
27.

Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study.

Monárrez-Espino J, Galanti MR, Hansson J, Janszky I, Söderberg-Löfdal K, Möller J.

Nicotine Tob Res. 2018 Apr 2;20(5):606-613. doi: 10.1093/ntr/ntx131.

PMID:
28595356
28.

Stora framsteg för systemisk behandling vid malignt melanom.

Ullenhag G, Hansson J, Ny L.

Lakartidningen. 2017 May 9;114. pii: ELM9. Swedish.

29.

[Melanoma in places other than the skin: eye and mucous membrane melanomas].

All-Eriksson C, Seregard S, Hansson J.

Lakartidningen. 2017 May 9;114. pii: ELAR. Swedish. No abstract available.

30.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.

31.

Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma.

Vikingsson S, Dahlberg JO, Hansson J, Höiom V, Gréen H.

Anal Bioanal Chem. 2017 Jun;409(15):3749-3756. doi: 10.1007/s00216-017-0316-8. Epub 2017 Apr 20.

32.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R.

Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368.

33.

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto PA, Hansson J, Masucci G.

Ann Oncol. 2017 Jul 1;28(7):1672-1673. doi: 10.1093/annonc/mdx177. No abstract available.

PMID:
28407116
34.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C.

Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4.

PMID:
28264791
35.

Symptom Management of the Patient with CKD: The Role of Dialysis.

Cabrera VJ, Hansson J, Kliger AS, Finkelstein FO.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):687-693. doi: 10.2215/CJN.01650216. Epub 2017 Feb 1. Review.

36.

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer.

Zirakzadeh AA, Kinn J, Krantz D, Rosenblatt R, Winerdal ME, Hu J, Hartana CA, Lundgren C, Bergman EA, Johansson M, Holmström B, Hansson J, Sidikii A, Vasko J, Marits P, Sherif A, Winqvist O.

Clin Immunol. 2017 Mar;176:63-70. doi: 10.1016/j.clim.2016.12.003. Epub 2016 Dec 24.

PMID:
28025135
37.

Capillary Pumping Independent of Liquid Sample Viscosity.

Guo W, Hansson J, van der Wijngaart W.

Langmuir. 2016 Dec 6;32(48):12650-12655. Epub 2016 Nov 14.

PMID:
27798835
38.

Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.

Rosenblatt R, Johansson M, Alamdari F, Sidiki A, Holmström B, Hansson J, Vasko J, Marits P, Gabrielsson S, Riklund K, Winqvist O, Sherif A.

World J Urol. 2017 Jun;35(6):921-927. doi: 10.1007/s00345-016-1952-x. Epub 2016 Oct 13.

39.

Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma.

Hansson J, Lindgren D, Nilsson H, Johansson E, Johansson M, Gustavsson L, Axelson H.

Clin Cancer Res. 2017 Apr 15;23(8):2105-2115. doi: 10.1158/1078-0432.CCR-16-0496. Epub 2016 Sep 23.

40.

Co-Leadership - A Management Solution for Integrated Health and Social Care.

Klinga C, Hansson J, Hasson H, Sachs MA.

Int J Integr Care. 2016 May 23;16(2):7. doi: 10.5334/ijic.2236.

41.

Surgical outcomes in patients with cutaneous malignant melanoma in Europe - a systematic literature review.

Costa Svedman F, Spanopoulos D, Taylor A, Amelio J, Hansson J.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):603-615. doi: 10.1111/jdv.13950. Epub 2016 Oct 4. Review.

PMID:
27580240
42.

Epidemiology of cutaneous melanoma in Sweden-Stage-specific survival and rate of recurrence.

Rockberg J, Amelio JM, Taylor A, Jörgensen L, Ragnhammar P, Hansson J.

Int J Cancer. 2016 Dec 15;139(12):2722-2729. doi: 10.1002/ijc.30407. Epub 2016 Sep 22.

43.

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Höiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM.

Hum Genet. 2016 Nov;135(11):1241-1249. Epub 2016 Jul 23.

44.

Experiences of security and continuity of care: Patients' and families' narratives about the work of specialized palliative home care teams.

Klarare A, Rasmussen BH, Fossum B, Fürst CJ, Hansson J, Hagelin CL.

Palliat Support Care. 2017 Apr;15(2):181-189. doi: 10.1017/S1478951516000547. Epub 2016 Jul 22.

PMID:
27443410
45.

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.

Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J.

Clin Epidemiol. 2016 May 26;8:109-22. doi: 10.2147/CLEP.S99021. eCollection 2016. Review.

46.

Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.

Helgadottir H, Höiom V, Tuominen R, Nielsen K, Jönsson G, Olsson H, Hansson J.

J Natl Cancer Inst. 2016 Jun 10;108(11). doi: 10.1093/jnci/djw135. Print 2016 Nov.

PMID:
27287845
47.

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group.

Melanoma Res. 2016 Aug;26(4):367-76. doi: 10.1097/CMR.0000000000000237.

PMID:
27076041
48.

The role of germline alterations in the DNA damage response genes BRIP1 and BRCA2 in melanoma susceptibility.

Tuominen R, Engström PG, Helgadottir H, Eriksson H, Unneberg P, Kjellqvist S, Yang M, Lindén D, Edsgärd D, Hansson J, Höiom V.

Genes Chromosomes Cancer. 2016 Jul;55(7):601-11. doi: 10.1002/gcc.22363. Epub 2016 May 2.

PMID:
27074266
49.

We Use Bioincompatible Peritoneal Dialysis Solutions.

Troidle L, Hansson J, Juergensen P, Finkelstein FO.

Semin Dial. 2016 Jul;29(4):263-4. doi: 10.1111/sdi.12490. Epub 2016 Apr 8.

PMID:
27061506
50.

Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.

Simberg-Danell C, Lyth J, Månsson-Brahme E, Frohm-Nilsson M, Carstensen J, Hansson J, Eriksson H.

Int J Cancer. 2016 Aug 1;139(3):543-53. doi: 10.1002/ijc.30103. Epub 2016 Apr 19.

Supplemental Content

Loading ...
Support Center